Eli Lilly and Company
PAN-ELR+ CXC CHEMOKINE ANTIBODIES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA
Last updated:
Abstract:
Provided herein are methods and uses of antibodies against ELR+ CXC chemokines for the treatment of hidradenitis suppurativa. Also provided are doses and dosing regimens for the methods and uses of antibodies against ELR+ CXC chemokines for the treatment of hidradenitis suppurativa.
Status:
Application
Type:
Utility
Filling date:
15 Oct 2019
Issue date:
4 Nov 2021